Gilead Sciences Statement on Request to Rescind Remdesivir Orphan Drug Designation

March 25, 2020 -- Gilead has submitted a request to the U.S. Food and Drug Administration to rescind the orphan drug designation it was granted for the investigational antiviral remdesivir for the treatment of COVID-19 and is waiving all benefits...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials